INVA NASDAQ
Innoviva, Inc.
1W: -1.6%
1M: -1.4%
3M: -3.2%
YTD: +5.4%
1Y: +18.2%
3Y: +63.1%
5Y: +27.6%
$20.94
-0.11 (-0.52%)
Pre-Market: $21.21 (+0.27, +1.29%)
Weekly Expected Move ±3.5%
$19
$20
$21
$21
$22
Credit Risk of going bust: lower than 82% of companies Debt: 15.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.21 (down 99%), Innoviva, Inc. would be worth roughly what it owes.
Total debt $269.7M against a stock market value of $1.51B.
Distance to default 10.31 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $129.2M (short-term plus half of long-term), stock volatility 26.8%; Altman Z'' 9.09. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.21 (down 99%), Innoviva, Inc. would be worth roughly what it owes.
Total debt $269.7M against a stock market value of $1.51B.
Distance to default 10.31 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $129.2M (short-term plus half of long-term), stock volatility 26.8%; Altman Z'' 9.09. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (46)
40,654 Shares of Innoviva, Inc. $INVA Purchased by Iridian Asset Management LLC CT
Innoviva, Inc. (NASDAQ:INVA) Stock Has Average Target Price of $39.25
Do Options Traders Know Something About Innoviva Stock We Don't?
INVA vs. MRK: Which Stock Is the Better Value Option?
5 Attractive Low Price-to-Sales Stocks With Promising Upside Potential
Should Value Investors Buy Innoviva (INVA) Stock?
Innoviva, Inc. $INVA Shares Newly Bought by Bank of America Corp DE
Bank of America Corp DE Invests $37.87 Million in Innoviva, Inc. $INVA
Baird Financial Group Inc. Makes New $6.23 Million Investment in Innoviva, Inc. $INVA
Legal & General Group Plc Takes $3.88 Million Position in Innoviva, Inc. $INVA
Hsbc Holdings PLC Buys Shares of 49,428 Innoviva, Inc. $INVA
Hsbc Holdings PLC Buys Shares of 49,428 Innoviva, Inc. $INVA
Innoviva, Inc. (NASDAQ:INVA) Receives $34.75 Average Target Price from Analysts
Bank of America Corp DE Has $37.75 Million Stake in Innoviva, Inc. $INVA
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
Merck (MRK) Reports Q2 Loss, Beats Revenue Estimates
AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates
Innoviva, Inc. (NASDAQ:INVA) Receives $36.20 Consensus Price Target from Brokerages
Dimensional Fund Advisors LP Acquires 76,026 Shares of Innoviva, Inc. $INVA
AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?
Bayer (BAYRY) Moves 17.0% Higher: Will This Strength Last?
Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty Strength
Innoviva (INVA) Tops Q1 Earnings Estimates
Earnings Scheduled For May 6, 2026
Pfizer (PFE) Q1 Earnings and Revenues Top Estimates
Merck (MRK) Reports Q1 Loss, Tops Revenue Estimates
Innoviva, Inc. (NASDAQ:INVA) Given Consensus Recommendation of “Moderate Buy” by Brokerages
3 Bargain-Cheap Small Caps Worth a Second Look
Innoviva (NASDAQ:INVA) Shares Cross Above 200 Day Moving Average – Here’s What Happened
Analysts Set Innoviva, Inc. (NASDAQ:INVA) Price Target at $34.80
American Century Companies Inc. Buys 284,253 Shares of Innoviva, Inc. $INVA
HC Wainwright Forecasts Innoviva FY2027 Earnings
HC Wainwright Brokers Reduce Earnings Estimates for Innoviva
Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Innoviva, Inc. (NASDAQ:INVA) Receives Average Recommendation of “Moderate Buy” from Brokerages
Innoviva GAAP EPS of $1.94, revenue of $114.6M
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
SG Americas Securities LLC Raises Position in Innoviva, Inc. $INVA
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
Boston Partners Boosts Holdings in Innoviva, Inc. $INVA
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
Innoviva, Inc. (NASDAQ:INVA) Receives Consensus Recommendation of “Moderate Buy” from Analysts